From: Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics
 | BMD <70 % of YAM | BMD ≥70 % of YAM | p value |
---|---|---|---|
Age | 65.0 (58.0–69.0) | 58.0 (53.0–66.0) | 0.0044* |
Proportion female | 93.0Â % | 77.9Â % | 0.0079* |
Disease duration (year) | 15.0 (8.0–20.0) | 8.0 (4.0–15.0) | 0.0004* |
BMI | 21.4 ± 2.8 | 23.6 ± 3.3 | <0.0001* |
Rate of rheumatoid vasculitis | 1.8Â % | 1.6Â % | 0.67 |
Proportion taking methylprednisolone | 45.6Â % | 40.3Â % | 0.52 |
Dose of methylprednisolone (mg) | 2.0 (1.0–3.5) | 3.3 (2.0–6.0) | 0.65 |
CRP (mg/dL) | 0.09 (0.03–0.31) | 0.08 (0.03–0.37) | 0.89 |
DAS28-CRP | 2.63 (1.88–3.38) | 2.50 (1.70–3.30) | 0.49 |
CDAI | 6.70 (2.90–14.90) | 5.80 (2.60–12.95) | 0.54 |
SDAI | 6.95 (3.05–14.10) | 6.30 (2.74–12.94) | 0.58 |
MHAQ score | 9.00 (1.00–14.00) | 4.00 (0.00–8.00) | 0.002* |
History of proximal femoral fracture | 2/57 | 0/129 | 0.087 |
History of thoracic or lumbar vertebral fracture | 17/57 | 9/129 | <0.001* |
Duration of biologics therapy | 4.2 ± 2.6 | 3.6 ± 2.3 | 0.166 |